• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.46
  • VXN 18.19
  • VXO 14.86
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
SGEN (Seattle Genetics Inc.)
Last Trade 69.975 Dividend/Share 0 PE Ratio -42.93
Date 10:35:56 AM Dividend Yield 0.000 Return on Assets -19
Change 0.815 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -1.43 Price/Sale 17.108
Ask 70.02 LatestEPS Date 2018-12-31 Price to Book 8.61
Volume 1836 EPS ttm -1.630 Institutional % 128.7
Avg Volume 0.89M Shares Outstanding 160.56M Insider % null
Open 69.25 Float 158.07M Short Ratio null
Prev Close 69.16 Return On Equity -23.17 5 Year Change % 0.273
High 70.34 Consensus EPS -0.39 2 Year Change % 0.053
Low 68.72 No. of Estimate 8.000 1 Year Change % 0.277
52 Week High 84.37 EPS Surprise $ null YTD Change % 0.203
52 Week Low 47.75 EPS Surprise Percent -46.1538 6 Month Change % -0.071
52 Week Change 27.814 EBITDA 0M 3 Month Change % 0.212
50 Day MA 66.351 Revenue 0M 1 Month Change % -0.022
200 Day MA Gross Profit 0M 5 Day Change % 0.009
Market Cap 11104.41M Cash 0M 30 Day Change % -0.003
Beta 2.296837 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.